GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Calidi Biotherapeutics CLDI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.73

+4.71%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Calidi Biotherapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Calidi Biotherapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on NYSE under the ticker CLDI. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2022, it reported revenue of $45,000.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
10 Sept 2021
Head office
4475 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. James SchoeneckIndependent Chairman of the Board, since 2020$79,352
  • Dr. Eric PomaChief Executive Officer, Director, since 2025
  • Mr. Andrew JacksonChief Financial Officer, Corporate Secretary$516,880
  • Ms. Wendy Pizarro CampbellChief Administrative Officer, Chief Legal Officer, Chief Diversity Officer, Corporate Secretary$484,015
  • Dr. Travis CliftonChief Medical Officer
  • Mr. Allan CamaisaIndependent Director, since 2018$509,121
  • Mr. Scott LeftwichIndependent Director$69,352
  • Col. (Retd.) George PeoplesIndependent Director$43,097
  • Mr. Alan StewartIndependent Director$74,352

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Calidi Biotherapeutics Inc advances allogeneic stem cell platforms for oncology treatments including CLD-101 and CLD-201.
  • The company's dual approach targets metastatic disease prevention and treatment using oncolytic viruses.
  • First Light Acquisition Group's IPO on 10 September 2021 provided capital for development.

Weaknesses

  • The company's focus on allogeneic stem cell platforms may limit immediate market entry.
  • CLD-101 and CLD-201 are still in development stages without approved products.
  • San Diego headquarters may restrict access to broader biotech talent pools.

Opportunities

  • Expanding oncology indications for CLD-101 and CLD-201 could increase market reach.
  • Partnerships with major oncology centers could accelerate clinical trials.
  • Growing demand for targeted cancer immunotherapies presents a significant market opportunity.

Threats

  • Competition from established biotech firms in the oncology sector remains high.
  • Regulatory hurdles for new cell-based therapies could delay approvals.
  • Financial constraints may impact ongoing research and development efforts.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.